Rodano, Italy

Barbara Novo

This inventor holds 5 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Olon S.p.a.. Active years: 2017-2023.

USPTO Granted Patents = 5 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations by Barbara Novo

Introduction

Barbara Novo is a prominent inventor based in Rodano, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative processes for drug preparation. With a total of five patents to her name, her work has had a substantial impact on the treatment of various medical conditions.

Latest Patents

One of her latest patents is a process for the preparation of Apalutamide. This invention relates to a method for synthesizing Apalutamide, which is a latest-generation androgen receptor inhibitor used to treat non-metastatic castration-resistant prostate cancer. Another notable patent is for the preparation of pimavanserin base. This process involves several steps, including the conversion of specific compounds to yield pimavanserin base with high purity and yield.

Career Highlights

Barbara Novo is currently employed at Olon S.p.a., where she continues to innovate in the pharmaceutical sector. Her expertise in drug synthesis has positioned her as a valuable asset to her company and the industry at large.

Collaborations

Some of her coworkers include Jacopo Bonanomi and Stella Defiore, who contribute to her projects and research endeavors.

Conclusion

Barbara Novo's contributions to pharmaceutical innovations through her patents demonstrate her commitment to advancing medical science. Her work continues to influence the development of effective treatments for serious health conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…